Drugmaker Sun Pharmaceutical Industries (Sun Pharma) is expected to report a muted net profit for the June quarter (Q1FY24) when it announces its earnings on Thursday, August 3. The pressure on earnings is likely due to flat growth for the arm Taro Pharma, weak US generic sales as a result of product restrictions at… Continue reading Sun Pharma Q1 profit may be weighed by weak US specialty sales and Taro nos